Clinical Trial Update: Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy

View source ↗

Summary

A completed study in pancreatic ductal adenocarcinoma shows that the dynamics of mesenchymal circulating tumor cell ratios during neoadjuvant/conversion therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Guo ShiWei | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Circulating Tumor Cells (CTCs) | Status: COMPLETED